Table 3

Clinical, functional, disease activity and serological parameters of naïve (n=227) and biological agents failure (n=381) in patients with PsA during 24 months follow up

T0T6T12T24
TJ (0–68), mean (SD)
 Group A8.20 (6.71)3.47 (4.90)2.11 (3.47)0.54 (1.02)
 Group B7.91 (6.88)3.75 (5.18)3.27 (5.38)2.11 (3.57)
 P valuensnsns0.03
SJ (0–66), mean (SD)
 Group A2.19 (2.87)0.58 (1.25)0.51 (1.97)0.15 (0.43)
 Group B2.28 (2.79)0.97 (1.67)0.66 (1.80)0.32 (0.79)
 P valuensnsnsns
LEI (0–6), mean (SD)
 Group A1.91 (1.92)0.94 (1.37)0.30 (0.69)0.13 (0.40)
 Group B1.44 (1.76)0.83 (1.51)0.43 (1.08)0.21 (0.70)
 P valuensnsnsns
Dactylitis (0–20) number digit, mean (SD)
 Group A0.22 (0.83)0.07 (0.62)0.03 (0.29)0.02 (0.17)
 Group B0.31 (1.48)0.08 (0.32)0.04 (0.26)0.02 (0.13)
 P valuensnsnsns
PASI (0–72), mean (SD)
 Group A4.06 (7.09)1.63 (3.55)0.61 (1.63)0.23 (0.55)
 Group B4.34 (7.54)1.73 (4.15)0.94 (2.49)1.14 (3.76)
 P valuensnsns0.04
ESR (0–25) (mm/hour), mean (SD)
 Group A21.24 (19.32)14.23 (11.88)13.86 (12.54)11.98 (10.44)
 Group B21.24 (19.32)16.62 (13.74)15.42 (14.11)16.10 (13.02)
 P valuensns0.050.03
CRP (0–6) (mg/L), mean (SD)
 Group A6.01 (9.14)3.13 (3.88)2.66 (3.50)2.12 (3.06)
 Group B6.01 (9.14)4.72 (3.77)3.84 (5.57)4.04 (6.03)
 P valuensnsns0.05
DAPSA (0–164), mean (SD)
 Group A25.24 (10.91)12.06 (8.49)10.29 (9.22)8.15 (7.95)
 Group B25.36 (11.31)15.34 (10.18)12.99 (10.21)9.42 (8.21)
 P valuens0.05nsns
ASDAS (0–6), mean (SD)
 Group A3.50 (0.59)2.08 (0.93)1.88 (0.91)1.34 (0.42)
 Group B3.12 (0.99)2.12 (1.09)1.80 (1.07)1.72 (0.76)
 P valuensnsnsns
HAQ-S (0–8), mean (SD)
 Group A1.11 (0.74)0.69 (0.56)0.47 (0.55)0.24 (0.35)
 Group B1.39 (0.87)1.03 (0.73)0.83 (0.75)0.65 (0.70)
 P valuens0.05nsns
VAS-pain (0–10), mean (SD)
 Group A6.62 (1.73)4.07 (2.30)2.78 (2.46)1.62 (1.72)
 Group B6.76 (1.65)4.43 (2.26)3.56 (2.50)3.00 (2.45)
 P valuensns0.050.04
VAS-gh (0–10), mean (SD)
 Group A5.89 (1.64)3.95 (2.24)2.43 (2.27)1.34 (1.66)
 Group B7.01 (6.08)4.43 (2.21)3.52 (2.46)3.01 (2.40)
 P valuensns0.050.03
BASDAI (0–10), mean (SD)
 Group A5.23 (2.08)3.34 (1.95)3.06 (1.96)2.14 (1.39)
 Group B5.21 (2.22)3.62 (2.82)3.51 (2.25)2.77 (1.66)
 P valuensnsnsns
BASFI (0–10), mean (SD)
 Group A5.02 (2.18)3.51 (1.94)2.54 (1.59)2.01 (0.81)
 Group B5.26 (2.12)3.85 (2.07)2.99 (1.99)2.66 (1.45)
 P valuensnsnsns
  • Data are expressed as mean (SD). P≤0.05. Values were computed by means of a χ2 test (for proportion) or Wilcoxon’s test (for continuous data).

  • The italics character was used to mark the p value.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; ESR, erythrocyte sedimentation rate; Group A, naïve to TNF inhibitors; Group B, TNF inhibitors and IL-12/23 inhibitors failure; HAQ, Health Assessment Questionnaire modified for spondyloarthritis; LEI, Leeds Enthesitis Index; ns, not statistically significant; PASI, Psoriasis Area Severity Index; SJ, swollen joint; TJ, tender joint; TNF, tumour necrosis factor; VAS-gh, Visual Analogue Scale global health; VAS-pain, Visual Analogue Scale pain.